Introduction: New data continue to emerge related to safety and efficacy of emerging SGLT1 and 2 inhibitors. We sought to assess the effect of online education designed to improve the knowledge and confidence of primary care physicians (PCPs), diabetologists and endocrinologists (D/Es), and nurses/nurse practitioners (NPs) in emerging therapies for diabetes management.

Methods: The education consisted of a 30-minute continuing medical education (CME)-certified roundtable discussion among 3 expert faculty. A 3-question knowledge and 1-question confidence linked pre-/post-assessment study design with McNemar’s chi-squared test (5% significance level, P <.05) assessed educational effect. The activity launched September 26, 2018 and data collected through October 5, 2018.

Results: Improvements were demonstrated by all specialties (PCP N=324, D/E N=104, nurse/NP N=1519): 24% more PCPs (P<.0001), 20% more D/Es (P=.0032), and 4% more nurses/NPs (P=.0251) correctly identified the mechanism of action of dual SGLT1/SGLT2 inhibitors. 38% of PCPs, 27% of D/Es, and 28% of NPs reported increased confidence in the treatment of type 1 diabetes with non-insulin therapies, specifically SGLT type 1 and SGLT type 2 inhibition. Continued knowledge gaps were identified for all specialties: 72% of PCPs, 65% of D/Es, and 66% of nurses/NPs failed to recognize safety and efficacy data for an emerging dual SGLT1/SGLT2 inhibitors. 40% of PCPs, 17% of D/Es, and 55% of nurses/NPs incorrectly identified a candidate for dual SGLT1/SGLT2 therapy 45% of PCPs, 32% of D/Es, and 69% of nurses/NPs failed to recognize the mechanism of action of dual SGLT1/SGLT2 inhibitors.

Conclusion: This study demonstrates the success of an online CME-certified roundtable discussion on improving clinical knowledge and confidence of PCPs, D/Es, and nurses/NPs related to dual SGLT1/SGLT2 inhibitors when treating patients with T1D. Continued knowledge gaps were identified for future education.

Disclosure

A. Larkin: None. M. LaCouture: None. A. Le: None.

Funding

Sanofi U.S.; Lexicon Pharmaceuticals

© 2019 by the American Diabetes Association.
2019
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.